Goldman Sachs raised the firm’s price target on Edwards Lifesciences (EW) to $101 from $89 and keeps a Buy rating on the shares following Q2 results. The firm notes the company updated full year FXN sales growth guidance from 8%-10% to 9%-10%. Goldman also believes Q2 represented a turning point in Edwards’ business and says it confirms its view that the company should return to double-digit sustainable top-line growth.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target raised to $95 from $87 at Mizuho
- Early notable gainers among liquid option names on July 25th
- Edwards Lifesciences price target raised to $95 from $90 at Stifel
- Edwards Lifesciences price target raised to $80 from $77 at Evercore ISI
- Edwards Lifesciences price target raised to $79 from $78 at Baird